[PDF][PDF] Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement

SM Lim, HR Kim, JS Lee, KH Lee, YG Lee… - Journal of clinical …, 2017 - researchgate.net
SM Lim, HR Kim, JS Lee, KH Lee, YG Lee, YJ Min, EK Cho, SS Lee, BS Kim, MY Choi…
Journal of clinical oncology, 2017researchgate.net
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer
Harboring ROS1 Rearrangement Page 1 JOURNAL OF CLINICAL ONCOLOGY ORIGINAL
REPORT Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell
Lung Cancer Harboring ROS1 Rearrangement Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee,
Ki Hyeong Lee, Yun-Gyoo Lee, Young Joo Min, Eun Kyung Cho, Sung Sook Lee, Bong-Seog
Kim, Moon Young Choi, Hyo Sup Shim, Jin-Haeng Chung, Yoon La Choi, Min Jeong Lee …
Purpose
ROS1 rearrangement is a distinct molecular subset of non–small-cell lung cancer (NSCLC). We investigated the efficacy and safety of ceritinib in patients with ROS1-rearranged NSCLC.
researchgate.net